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Background
Across the MVC development program, patients who
received MVC-containing regimens experienced greater
increases in CD4+ cell counts than those observed in
comparator arms in primary analyses. Here we present
longer term immunological data from this program.
Material and methods
Long-term (96 week) data from subjects with CCR5-tro-
pic HIV infection in the following ongoing MVC studies
were included in the analysis: (1) MOTIVATE study
(MVC QD and BID vs placebo (PBO), each combined
with optimized background therapy in treatment-experi-
enced [TE] subjects); and (2) MERIT study (MVC BID
vs EFV, each combined with ZDV/3TC in treatment-
naïve [TN] subjects). Additionally, interim week 24 data
from the ongoing 96-week 1078 study (MVC QD vs
TDF/FTC, each combined with ATV/r in TN subjects)
were summarized. Descriptive statistics are presented
for data at baseline and at week 96 (MERIT/MOTI-
VATE) or week 24 (1078) pertaining to change in CD4+
and CD8+ cells.
Results
Greater increases in CD4+ cells in MVC-containing
groups persisted through 96 weeks in the MOTIVATE
and MERIT studies, and through 24 weeks in the 1078
s t u d y( T a b l e1 ) .S i m i l a r l y ,changes in CD8+ cells from
baseline to weeks 96 or 24 favored MVC-containing
regimens in all three studies. In a combined LOCF ana-
lysis of patients from all three studies at week 24, CD4+
counts increased by a median 100.5 cells/µL in 1260
recipients of MVC-containing regimens, compared with
84.5 cells/µL in 631 recipients of comparator regimens;
CD8+ counts increased by a median 153 cells/µL in the
MVC group, compared with a decrease of 61 cells/µL in
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Table 1
Population Treatment-experienced Treatment-naive
Study MOTIVATE – 96 Weeks MERIT – 96 Weeks 1078 – 24 Weeks
Arm MVC QD MVC BID PBO MVC BID EFV MVC QD TDF/FTC
N 414 426 209 360 361 60 61
BL HIV RNA (median log10 cp/mL) 4.86 4.85 4.86 4.88 4.85 4.59 4.66
Baseline CD4 count (median cells/µL) 171 167 171 244.3 258.5 344.5 358.0
Baseline CD8 count (median cells/µL) 867.5 836.5 820.8 791.5 860.0 859.8 890.0
CD4 change from BL (median cells/µL) 89.0 112.5 21.0 224.3 195.0 195.3 173.0
CD8 change from BL (medican cells/µL) 138.0 157.0 31.5 -3.00 -94.5 4.5 -78.5
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of patients from the MOTIVATE and MERIT studies
showed median CD4+ increases from baseline of 129.5
and 100.3 cells/µL in the MVC (N=1177) and compara-
tor (N=554) groups, respectively; CD8+ changes were 96
and -72 cells/µL, respectively. In all studies, differences
in CD4+ and CD8+ counts between treatment groups
were independent of differences in viral load changes
(data not shown).
Conclusions
Greater increases in CD4+ and CD8+ counts were con-
sistently achieved with MVC-containing regimens, com-
pared to regimens without MVC, and persisted through
at least 2 years of therapy in both TN and TE patients.
These differences were independent of changes in HIV-
1 RNA and are evident with multiple different MVC-
containing regimens.
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